{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:11:10Z","timestamp":1790107870765,"version":"4.0.1"},"reference-count":84,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jbc.2026.113337","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:34:58Z","timestamp":1784216098000},"page":"113337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Engineering internally his-tagged ESX secretion system fusion antigens for tuberculosis nanoparticle vaccines"],"prefix":"10.1016","volume":"302","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0707-6863","authenticated-orcid":false,"given":"Wen-Ling","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina N.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1197-1391","authenticated-orcid":false,"given":"Brennen T.","family":"Troyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7363-4344","authenticated-orcid":false,"given":"Matthew","family":"Hvasta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kuhlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Obregon-Henao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9052-884X","authenticated-orcid":false,"given":"Jonathan F.","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2026.113337_bib1","series-title":"Global Tuberculosis Report 2024 Geneva","year":"2024"},{"key":"10.1016\/j.jbc.2026.113337_bib2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jbc.2026.113337_bib3","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S2213-2600(15)00037-5","article-title":"Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial","volume":"3","author":"Ndiaye","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.jbc.2026.113337_bib4","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ebiom.2016.04.010","article-title":"Safety and immunogenicity of the recombinant BCG vaccine AERAS-422 in healthy BCG-naive adults: a randomized, active-controlled, first-in-human phase 1 trial","volume":"7","author":"Hoft","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jbc.2026.113337_bib5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41541-018-0057-5","article-title":"The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial","volume":"3","author":"Coler","year":"2018","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.jbc.2026.113337_bib6","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.jbc.2026.113337_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2016.05.001","article-title":"Vaccine technologies: from whole organisms to rationally designed protein assemblies","volume":"120","author":"Karch","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jbc.2026.113337_bib8","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","article-title":"Phase 2b controlled trial of M72\/AS01(E) vaccine to prevent tuberculosis","volume":"379","author":"Van Der Meeren","year":"2018","journal-title":"N. Engl. J Med."},{"key":"10.1016\/j.jbc.2026.113337_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.jbc.2026.113337_bib10","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jbc.2026.113337_bib11","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.4049\/jimmunol.154.7.3359","article-title":"Recall of long-lived immunity to Mycobacterium tuberculosis infection in mice","volume":"154","author":"Andersen","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.jbc.2026.113337_bib12","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1128\/JCM.38.9.3285-3290.2000","article-title":"Molecular and immunological characterization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG","volume":"38","author":"Dillon","year":"2000","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jbc.2026.113337_bib13","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.tube.2015.07.001","article-title":"A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents","volume":"95","author":"Carpenter","year":"2015","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.jbc.2026.113337_bib14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1054\/tuld.2000.0244","article-title":"An esat6 knockout mutant of Mycobacterium bovis produced by homologous recombination will contribute to the development of a live tuberculosis vaccine","volume":"80","author":"Wards","year":"2000","journal-title":"Tuber Lung Dis."},{"key":"10.1016\/j.jbc.2026.113337_bib15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/microbiolspec.BAI-0024-2019","article-title":"Infect and inject: how Mycobacterium tuberculosis exploits its major virulence-associated type VII secretion system, ESX-1","volume":"7","author":"Tiwari","year":"2019","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.jbc.2026.113337_bib16","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1038\/sj.emboj.7600732","article-title":"Structure and function of the complex formed by the tuberculosis virulence factors CFP-10 and ESAT-6","volume":"24","author":"Renshaw","year":"2005","journal-title":"EMBO J."},{"key":"10.1016\/j.jbc.2026.113337_bib17","doi-asserted-by":"crossref","first-page":"17681","DOI":"10.1074\/jbc.M800123200","article-title":"Molecular features governing the stability and specificity of functional complex formation by Mycobacterium tuberculosis CFP-10\/ESAT-6 family proteins","volume":"283","author":"Lightbody","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2026.113337_bib18","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/ni1468","article-title":"Direct extracellular interaction between the early secreted antigen ESAT-6 of Mycobacterium tuberculosis and TLR2 inhibits TLR signaling in macrophages","volume":"8","author":"Pathak","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jbc.2026.113337_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002378","article-title":"Early secreted antigen ESAT-6 of Mycobacterium tuberculosis promotes protective T helper 17 cell responses in a toll-like receptor-2-dependent manner","volume":"7","author":"Chatterjee","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jbc.2026.113337_bib20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3389\/fcimb.2018.00327","article-title":"Mycobacterium tuberculosis virulent factor ESAT-6 drives macrophage differentiation toward the pro-inflammatory M1 phenotype and subsequently switches it to the anti-inflammatory M2 phenotype","volume":"8","author":"Refai","year":"2018","journal-title":"Front. Cell Infect. Microbiol."},{"key":"10.1016\/j.jbc.2026.113337_bib21","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1084\/jem.20080353","article-title":"Delayed protection by ESAT-6-specific effector CD4+ T cells after airborne M. tuberculosis infection","volume":"205","author":"Gallegos","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jbc.2026.113337_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.585359","article-title":"Rescuing ESAT-6 specific CD4 T cells from terminal differentiation is critical for long-term control of murine Mtb infection","volume":"11","author":"Clemmensen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jbc.2026.113337_bib23","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20041690","article-title":"Cytolytic CD8+ T cells recognizing CFP10 are recruited to the lung after Mycobacterium tuberculosis infection","volume":"200","author":"Kamath","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jbc.2026.113337_bib24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1128\/IAI.02493-14","article-title":"CFP-10 from Mycobacterium tuberculosis selectively activates human neutrophils through a pertussis toxin-sensitive chemotactic receptor","volume":"83","author":"Welin","year":"2015","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jbc.2026.113337_bib25","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nm859","article-title":"Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis","volume":"9","author":"Pym","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.jbc.2026.113337_bib26","doi-asserted-by":"crossref","first-page":"29993","DOI":"10.1074\/jbc.M111.248732","article-title":"Solution structure of the Mycobacterium tuberculosis EsxG.EsxH complex: functional implications and comparisons with other M. tuberculosis Esx family complexes","volume":"286","author":"Ilghari","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2026.113337_bib27","doi-asserted-by":"crossref","first-page":"6340","DOI":"10.1128\/JB.00756-09","article-title":"Characterization of a Mycobacterium tuberculosis ESX-3 conditional mutant: essentiality and rescue by iron and zinc","volume":"191","author":"Serafini","year":"2009","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.jbc.2026.113337_bib28","doi-asserted-by":"crossref","first-page":"18792","DOI":"10.1073\/pnas.0900589106","article-title":"Mycobacterial Esx-3 is required for mycobactin-mediated iron acquisition","volume":"106","author":"Siegrist","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2026.113337_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003734","article-title":"Mycobacterium tuberculosis type VII secreted effector EsxH targets host ESCRT to impair trafficking","volume":"9","author":"Mehra","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jbc.2026.113337_bib30","doi-asserted-by":"crossref","first-page":"E348","DOI":"10.1073\/pnas.1523321113","article-title":"Separable roles for mycobacterium tuberculosis ESX-3 effectors in iron acquisition and virulence","volume":"113","author":"Tufariello","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2026.113337_bib31","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.4049\/jimmunol.179.6.3973","article-title":"Induction of CD8 T cells against a novel epitope in TB10.4: correlation with mycobacterial virulence and the presence of a functional region of difference-1","volume":"179","author":"Billeskov","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.jbc.2026.113337_bib32","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1128\/IAI.02086-05","article-title":"High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection","volume":"74","author":"Hervas-Stubbs","year":"2006","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jbc.2026.113337_bib33","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1128\/IAI.70.10.5446-5453.2002","article-title":"Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family","volume":"70","author":"Skjot","year":"2002","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jbc.2026.113337_bib34","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1055\/a-1785-3936","article-title":"A new intranasal Influenza vector-based vaccine TB\/FLU-04L against tuberculosis: preclinical safety studies","volume":"72","author":"Buzitskaya","year":"2022","journal-title":"Drug Res. (Stuttg)"},{"key":"10.1016\/j.jbc.2026.113337_bib35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1055\/a-1771-5985","article-title":"Preclinical safety evaluation: acute and repeated-dose toxicity of a new intranasal recombinant Vector vaccine TB\/FLU-04L against tuberculosis","volume":"72","author":"Stosman","year":"2022","journal-title":"Drug Res. (Stuttg)"},{"key":"10.1016\/j.jbc.2026.113337_bib36","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.3390\/ijms24087439","article-title":"Preclinical evaluation of TB\/FLU-04L-An intranasal Influenza vector-based boost vaccine against tuberculosis","volume":"24","author":"Shurygina","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbc.2026.113337_bib37","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/vaccines9040394","article-title":"Mucosal influenza vector vaccine carrying TB10.4 and HspX antigens provides protection against Mycobacterium tuberculosis in mice and Guinea pigs","volume":"9","author":"Sergeeva","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jbc.2026.113337_bib38","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3390\/vaccines9111273","article-title":"Enhancement of the local CD8(+) T-Cellular immune response to Mycobacterium tuberculosis in BCG-primed mice after intranasal administration of influenza vector vaccine carrying TB10.4 and HspX antigens","volume":"9","author":"Vasilyev","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jbc.2026.113337_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196815","article-title":"A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis","volume":"13","author":"Leung-Theung-Long","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2026.113337_bib40","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/IAI.68.2.791-795.2000","article-title":"ESAT-6 subunit vaccination against Mycobacterium tuberculosis","volume":"68","author":"Brandt","year":"2000","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jbc.2026.113337_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.647220","article-title":"Subunit vaccine ESAT-6:c-di-AMP delivered by intranasal route elicits immune responses and protects against Mycobacterium tuberculosis infection","volume":"11","author":"Ning","year":"2021","journal-title":"Front. Cell Infect. Microbiol."},{"key":"10.1016\/j.jbc.2026.113337_bib42","doi-asserted-by":"crossref","first-page":"5677","DOI":"10.1016\/j.vaccine.2016.08.075","article-title":"Novel lipopeptides of ESAT-6 induce strong protective immunity against Mycobacterium tuberculosis: Routes of immunization and TLR agonists critically impact vaccine's efficacy","volume":"34","author":"Gupta","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jbc.2026.113337_bib43","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1021\/acsinfecdis.4c00771","article-title":"Testing the antigenic potential of transmembrane proteins to develop a thermostable tuberculosis MOF-liposomal vaccine","volume":"11","author":"Kumari","year":"2025","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.jbc.2026.113337_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080579","article-title":"ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination","volume":"8","author":"Hoang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2026.113337_bib45","doi-asserted-by":"crossref","first-page":"6774","DOI":"10.1038\/s41467-021-27029-6","article-title":"A phase I\/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients","volume":"12","author":"Jenum","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2026.113337_bib46","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1016\/j.vaccine.2015.06.051","article-title":"First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults","volume":"33","author":"Luabeya","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jbc.2026.113337_bib47","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13063-017-2354-0","article-title":"A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1\/IC31(R) in people living in a TB-endemic area","volume":"19","author":"Hussein","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.jbc.2026.113337_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114602","article-title":"Safety and immunogenicity of H1\/IC31(R), an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells\/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial","volume":"9","author":"Reither","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2026.113337_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039909","article-title":"The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity","volume":"7","author":"Billeskov","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2026.113337_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005139","article-title":"CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination","volume":"4","author":"Elvang","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2026.113337_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005930","article-title":"Protection and polyfunctional T cells induced by Ag85B-TB10.4\/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose","volume":"4","author":"Aagaard","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2026.113337_bib52","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.vaccine.2017.01.055","article-title":"Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials","volume":"35","author":"Norrby","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.jbc.2026.113337_bib53","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1016\/j.vaccine.2015.05.036","article-title":"The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial","volume":"33","author":"Geldenhuys","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jbc.2026.113337_bib54","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1714021","article-title":"Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination","volume":"379","author":"Nemes","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbc.2026.113337_bib55","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41541-024-00847-7","article-title":"BCG-booster vaccination with HSP90-ESAT-6-HspX-RipA multivalent subunit vaccine confers durable protection against hypervirulent Mtb in mice","volume":"9","author":"Kwon","year":"2024","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.jbc.2026.113337_bib56","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jmii.2014.03.005","article-title":"Recombinant tuberculosis vaccine AEC\/BC02 induces antigen-specific cellular responses in mice and protects Guinea pigs in a model of latent infection","volume":"48","author":"Lu","year":"2015","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.jbc.2026.113337_bib57","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3390\/vaccines7040166","article-title":"First-In-human trials of GamTBvac, a recombinant subunit tuberculosis vaccine candidate: safety and immunogenicity assessment","volume":"7","author":"Vasina","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jbc.2026.113337_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176784","article-title":"Multi-subunit BCG booster vaccine GamTBvac: assessment of immunogenicity and protective efficacy in murine and Guinea pig TB models","volume":"12","author":"Tkachuk","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2026.113337_bib59","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3390\/vaccines8040652","article-title":"Safety and immunogenicity of the GamTBvac, the recombinant subunit tuberculosis vaccine candidate: a phase II, multi-center, double-blind, randomized, placebo-controlled study","volume":"8","author":"Tkachuk","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jbc.2026.113337_bib60","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41541-023-00666-2","article-title":"A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG","volume":"8","author":"Dijkman","year":"2023","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.jbc.2026.113337_bib61","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1038\/s41467-021-26934-0","article-title":"A mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guerin","volume":"12","author":"Woodworth","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2026.113337_bib62","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1039\/C6MB00174B","article-title":"Fc-based delivery system enhances immunogenicity of a tuberculosis subunit vaccine candidate consisting of the ESAT-6:CFP-10 complex","volume":"12","author":"Farsiani","year":"2016","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.jbc.2026.113337_bib63","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijbiomac.2020.12.179","article-title":"High-yield production of major T-cell ESAT6-CFP10 fusion antigen of M. tuberculosis complex employing codon-optimized synthetic gene","volume":"171","author":"Gutierrez-Ortega","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jbc.2026.113337_bib64","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/s41565-018-0271-3","article-title":"A malaria vaccine adjuvant based on recombinant antigen binding to liposomes","volume":"13","author":"Huang","year":"2018","journal-title":"Nat. Nanotechnol"},{"key":"10.1016\/j.jbc.2026.113337_bib65","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41541-020-0173-x","article-title":"Antibody response of a particle-inducing, liposome vaccine adjuvant admixed with a Pfs230 fragment","volume":"5","author":"Huang","year":"2020","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.jbc.2026.113337_bib66","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12936-020-03368-5","article-title":"Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose","volume":"19","author":"Huang","year":"2020","journal-title":"Malar J."},{"key":"10.1016\/j.jbc.2026.113337_bib67","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s42003-022-03688-z","article-title":"Vaccine co-display of CSP and Pfs230 on liposomes targeting two Plasmodium falciparum differentiation stages","volume":"5","author":"Huang","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.jbc.2026.113337_bib68","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.vaccine.2019.10.073","article-title":"Immunogenicity of the Lyme disease antigen OspA, particleized by cobalt porphyrin-phospholipid liposomes","volume":"38","author":"Federizon","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jbc.2026.113337_bib69","article-title":"SARS-CoV-2 RBD neutralizing antibody induction is enhanced by particulate vaccination","volume":"32","author":"Huang","year":"2020","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jbc.2026.113337_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202304534","article-title":"SARS-CoV-2 protein nanoparticle vaccines formed in situ from lyophilized lipids","volume":"20","author":"Jiao","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.jbc.2026.113337_bib71","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/s12916-022-02661-1","article-title":"Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine","volume":"20","author":"Lovell","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/j.jbc.2026.113337_bib72","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29927","article-title":"Interim safety and immunogenicity analysis of the EuCorVac-19 COVID-19 vaccine in a phase 3 randomized, observer-blind, immunobridging trial in the Philippines","volume":"96","author":"Lovell","year":"2024","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jbc.2026.113337_bib73","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3390\/vaccines13080776","article-title":"Year-long antibody response to the EuCorVac-19 SARS-CoV-2 vaccine in healthy filipinos","volume":"13","author":"Lovell","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jbc.2026.113337_bib74","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijid.2023.11.004","article-title":"One-year antibody durability induced by EuCorVac-19, a liposome-displayed COVID-19 receptor binding domain subunit vaccine, in healthy Korean subjects","volume":"138","author":"Lovell","year":"2024","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.jbc.2026.113337_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2026.128281","article-title":"A point-mutated Ag85B antigen improves recombinant bacterial expression and protects mice from aerosol M. tuberculosis challenge","volume":"76","author":"Hsu","year":"2026","journal-title":"Vaccine"},{"key":"10.1016\/j.jbc.2026.113337_bib76","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1007\/s00018-008-8228-6","article-title":"Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant","volume":"65","author":"Casella","year":"2008","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.jbc.2026.113337_bib77","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/SHK.0000000000000042","article-title":"The immunobiology of toll-like receptor 4 agonists: from endotoxin tolerance to immunoadjuvants","volume":"40","author":"Bohannon","year":"2013","journal-title":"Shock"},{"key":"10.1016\/j.jbc.2026.113337_bib78","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41541-017-0027-3","article-title":"Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNgamma response promoting vaccine immunogenicity","volume":"2","author":"Coccia","year":"2017","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.jbc.2026.113337_bib79","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3390\/pathogens11091035","article-title":"Intranasal Immunization with Liposome-Displayed Receptor-Binding Domain Induces Mucosal Immunity and Protection against SARS-CoV-2","volume":"11","author":"Huang","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.jbc.2026.113337_bib80","doi-asserted-by":"crossref","DOI":"10.1038\/srep20696","article-title":"Internal (His)(6)-tagging delivers a fully functional hetero-oligomeric class II chaperonin in high yield","volume":"6","author":"Paul","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jbc.2026.113337_bib81","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1038\/s41467-024-47492-1","article-title":"CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits","volume":"15","author":"Koornneef","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2026.113337_bib82","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20240496","article-title":"Deconvoluting the interplay of innate and adaptive immunity in BCG-induced nonspecific and TB-specific host resistance","volume":"222","author":"Hilligan","year":"2025","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jbc.2026.113337_bib85","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nchem.2236","article-title":"Functionalization of cobalt porphyrin-phospholipid bilayers with his-tagged ligands and antigens","volume":"7","author":"Shyo","year":"2015","journal-title":"Nat. Chem."},{"key":"10.1016\/j.jbc.2026.113337_bib86","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nmat2986","article-title":"Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents","volume":"10","author":"Lovell","year":"2011","journal-title":"Nat. Mater."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002192582602209X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002192582602209X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:51:49Z","timestamp":1790106709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002192582602209X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":84,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S002192582602209X"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2026.113337","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering internally his-tagged ESX secretion system fusion antigens for tuberculosis nanoparticle vaccines","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2026.113337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"113337"}}